Eupraxia Pharmaceuticals (EPRX) Non Operating Income (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Non Operating Income of $3.3 million for Q1 2026, up 821.81% year-over-year from $359739.0 in Q1 2025, and up 705.82% quarter-over-quarter from -$547377.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Non Operating Income (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Non Operating Income for 4 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 821.81% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $2.8 million (up 40.19% YoY), while the FY2025 annual figure was -$152522.0, down 112.1% from the prior year.
- Non Operating Income rose to $3.3 million in Q1 2026 per EPRX's latest filing, from -$547377.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $3.3 million in Q1 2026 and bottomed at -$547377.0 in Q4 2025.
- Historically, Non Operating Income has averaged $725612.3 across 4 years, with a median of $359739.0 in 2025.
- Annual changes were most pronounced in 2025 — Non Operating Income plunged 1018.81% — and 2026, when it soared 821.81%.
- Eupraxia Pharmaceuticals' Non Operating Income stood at $1.4 million in 2023, then slumped by 103.48% to -$48925.0 in 2024, then slumped by 1018.81% to -$547377.0 in 2025, then jumped by 705.82% to $3.3 million in 2026.
- Business Quant data shows EPRX's Non Operating Income at $3.3 million in Q1 2026, -$547377.0 in Q4 2025, and $513119.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 3.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.32 Mn |
| Dec 31, 2025 | -547,377.00 |
| Sep 30, 2025 | 513,119.00 |
| Jun 30, 2025 | -478,003.00 |
| Mar 31, 2025 | 359,739.00 |
| Dec 31, 2024 | -48,925.00 |
| Sep 30, 2024 | 281,901.00 |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 1.73 Mn |